Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today that Selexis and Symphogen A/S have entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment of various cancers and infectious diseases.

Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized mAb mixtures manufactured in a single batch.

“The SUREtechnology platform is a perfect fit for Symphogen’s novel MAb mixture approach for a multi-targeted MAb therapeutic with a single administration,” said Dr. Igor Fisch, CEO, Selexis SA. “Our technology allows Symphogen to achieve consistent production levels of all the MAb-expressing clonal cell lines in the mixture with no compromise on quality nor on stability.”

The Selexis SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel human DNA-based elements that control the dynamic organization of chromatin across mammalian cells by increasing transcription rates of transgene, by rendering the expression cassette independent of the locus of integration and thus allowing higher and more stable expression of any recombinant proteins. The SUREtechnology Platform™ improves the way cells are used in the discovery, development and manufacturing of recombinant proteins.

The Selexis SURE CHO-M Cell Line™ is a proprietary high-performance mammalian cell line derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line™ are well defined, and the feed strategy optimized allowing faster and more efficient scale-up into bioreactors.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies for biologic drug discovery, mammalian cell line development and scale-up to manufacturing of recombinant therapeutic proteins. With the Company’s SUREtechnology Platform™ biopharmaceutical companies can significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for the production of monoclonal antibodies (MAbs) and other recombinant proteins including difficult-to-express proteins such as plasma proteins, GPCRs and non-natural proteins such as fusion proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to late-stage clinical trials.